Spots Global Cancer Trial Database for nhl
Every month we try and update this database with for nhl cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | NCT03465540 | Multiple Myelom... Acute Myeloid L... Non-Hodgkins Ly... Myelodysplastic... AML MDS NHL | AMG 397 Dexamethasone Azacitidine | 18 Years - 65 Years | Amgen | |
| Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL) | NCT00717925 | Lymphoma, B-Cel... | Inotuzumab Ozog... | 20 Years - 74 Years | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy | NCT02178475 | Chemotherapy-in... | 18 Years - | Amgen | ||
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | NCT02631044 | Non-Hodgkin Lym... Diffuse Large B... Follicular Lymp... Mantle-cell Lym... Primary Mediast... | JCAR017 (lisoca... JCAR017 (lisoca... | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma | NCT00796731 | Lymphoma Non-Hodgkin | SAR3419 | 18 Years - | Sanofi | |
| A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant | NCT03739502 | AML NHL Hodgkin Disease All Myelodysplastic... | Hyperbaric oxyg... | 18 Years - 70 Years | University of Rochester | |
| Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia | NCT01516619 | Non-Hodgkin Lym... | Romiplostim | 18 Years - | IRCCS San Raffaele | |
| Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients | NCT04844866 | Diffuse Large B... | MB-CART2019.1 R-GemOx or BR p... | 18 Years - | Miltenyi Biomedicine GmbH | |
| Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders | NCT00636909 | AML ALL CML Chronic Pha... CLL MDS RELAPSED NON-HO... APLASTIC ANEMIA MULTIPLE MYELOM... MYELOPROLIFERAT... | Cyclophosphamid... fludarabine cyclosporine methotrexate G-CSF | - 65 Years | Beth Israel Deaconess Medical Center | |
| Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL | NCT01851551 | Non-Hodgkin's L... Diffuse Large B... Mantle Cell Lym... | Vincristine Sul... | 18 Years - | Acrotech Biopharma Inc. | |
| Infusion of Allogeneic, 3rd Party CD19-specific T Cells | NCT02274506 | Blood And Marro... Leukemia Lymphoma | Cyclophosphamid... Fludarabine T-Cell Infusion | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | NCT01306643 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma | NCT00285428 | Non-Hodgkin's L... | hA20-humanized ... | 18 Years - | Gilead Sciences | |
| Randomized Double Cord Blood Transplant Study | NCT00067002 | Leukemia, Lymph... Leukemia, Myelo... Leukemia, Myelo... Lymphoma, Non-H... | Expanded alloge... One Unmanipulat... Rituxan Melphalan Thiotepa Fludarabine Cyclophosphamid... Mesna Total body irra... | 1 Month - 80 Years | M.D. Anderson Cancer Center | |
| Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers | NCT00089596 | Acute Lymphocyt... Acute Myeloid L... Myelodysplastic... Non-Hodgkin Lym... Chronic Myeloge... | Expansion of um... | 12 Years - 60 Years | ViaCell | |
| A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System | NCT06385522 | NHL Cutaneous T Cel... Peripheral T-ce... | BITR2101 | 18 Years - | Boston Immune Technologies and Therapeutics | |
| Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL | NCT01585688 | Non-Hodgkin's L... Chronic Lymphoc... | hLL1-DOX (IMMU-... | 18 Years - | Gilead Sciences | |
| A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma | NCT00413036 | Lymphoma, Non-H... | lenalidomide | 18 Years - | Celgene | |
| Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection | NCT02836925 | Indolent B-cell... Hepatitis C | Ledipasvir+Sofo... Sofosbuvir+Velp... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma | NCT00283439 | Chemotherapy-In... Hodgkin's Lymph... Non-Hodgkin's L... Cancer Oncology Thrombocytopeni... | AMG 531 | 18 Years - | Amgen | |
| Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma | NCT01352312 | Chronic Lymphoc... B-Cell Non-Hodg... | Bendamustine Pentostatin Ofatumumab | 18 Years - | Thomas Jefferson University | |
| Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL | NCT00577161 | Non-Hodgkin's L... | fludarabine and... fludarabine, ri... | 18 Years - | CTI BioPharma | |
| Infusion of Allogeneic, 3rd Party CD19-specific T Cells | NCT02274506 | Blood And Marro... Leukemia Lymphoma | Cyclophosphamid... Fludarabine T-Cell Infusion | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintenance Therapy in Follicular B-Cell Lymphoma | NCT01560117 | Follicular T-NH... Rituximab Maint... | Rituximab | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG | NCT00061425 | Non-Hodgkin's L... Lymphoma, B-Cel... | radiolabeled ep... | 18 Years - | Gilead Sciences | |
| Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma | NCT00308087 | Lymphoma, Folli... | Sargramostim (L... Rituximab | 18 Years - | Sanofi | |
| First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 | NCT05737628 | Lymphoma | BYON4228 + Ritu... | 18 Years - | Byondis B.V. | |
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | NCT03019666 | Multiple Myelom... Non-Hodgkin Lym... Diffuse Large B... Mantle-Cell Lym... Follicular Lymp... Indolent B Cell... Primary Mediast... Lymphoplasmacyt... | Nicotinamide Ex... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | NCT04594642 | B-cell Non Hodg... Diffuse Large B... High-grade B-ce... Follicular Lymp... | AZD0486 IV | 18 Years - 130 Years | AstraZeneca | |
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | NCT03019666 | Multiple Myelom... Non-Hodgkin Lym... Diffuse Large B... Mantle-Cell Lym... Follicular Lymp... Indolent B Cell... Primary Mediast... Lymphoplasmacyt... | Nicotinamide Ex... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma | NCT02715843 | Non-Hodgkin's B... | MT-3724 | 18 Years - | Molecular Templates, Inc. | |
| STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma | NCT01653067 | Diffuse Large B... | Rituximab, Tems... | 18 Years - | University Hospital Heidelberg | |
| Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL | NCT05641428 | NHL DLBCL - Diffuse... | ARI-0001 Axi-cel | 18 Years - 80 Years | University Medical Center Groningen | |
| A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System | NCT06385522 | NHL Cutaneous T Cel... Peripheral T-ce... | BITR2101 | 18 Years - | Boston Immune Technologies and Therapeutics | |
| CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation | NCT00038818 | Chronic Myeloge... Multiple Myelom... Non Hodgkin's L... Hodgkin's Disea... Chronic Lymphoc... | CD8 Depleted Do... | - | M.D. Anderson Cancer Center | |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | NCT03740529 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... B-cell Lymphoma Small Lymphocyt... | Pirtobrutinib Venetoclax Rituximab | 18 Years - | Eli Lilly and Company | |
| Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL | NCT02151903 | B-cell Non-Hodg... | DI-Leu16-IL2 | 18 Years - | Alopexx Oncology, LLC | |
| Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapsed Non-Hodgkin's Lymphoma | NCT00147953 | Non-Hodgkin's L... | Rituximab Total nodal irr... | 18 Years - | University of Cologne | |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | NCT03314974 | Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M... | HSCT with TBI R... HSCT with Non-T... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) | NCT00499239 | Non-Hodgkin's L... Chronic Lymphoc... Multiple Myelom... | GS-9219 | 18 Years - | Gilead Sciences | |
| Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases | NCT00538551 | Hodgkin Disease Lymphoma, Non-H... | Database | 14 Years - 85 Years | King Faisal Specialist Hospital & Research Center | |
| Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL | NCT04206943 | Acute Lymphobla... Non Hodgkin Lym... | Car-T Cell Ther... | 3 Years - 65 Years | Acibadem University | |
| Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas | NCT01282424 | Follicular Lymp... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma | NCT01889797 | Indolent Non-Ho... | Arm A: Rituxima... Arm B: GA101 | 18 Years - | PrECOG, LLC. | |
| Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL | NCT05641428 | NHL DLBCL - Diffuse... | ARI-0001 Axi-cel | 18 Years - 80 Years | University Medical Center Groningen | |
| Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) | NCT00299494 | B-Cell Lymphoma | inotuzumab ozog... inotuzumab ozog... inotuzumab ozog... Rituximab | 18 Years - | Pfizer | |
| A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma | NCT00556699 | Non-Hodgkin's L... | rituximab SGN-40 | 18 Years - | Genentech, Inc. | |
| Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies | NCT03588598 | Chronic Lymphoc... Small Lymphocyt... B-Cell Non-Hodg... | SHC014748M | 18 Years - 75 Years | Nanjing Sanhome Pharmaceutical, Co., Ltd. | |
| Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement | NCT00992758 | Lymphoma, Non-H... | Iodine-131 Anti... | 18 Years - | GlaxoSmithKline | |
| CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies | NCT00968760 | Lymphoma B-cell Lymphoma | Leukapheresis Stem Cell Trans... CD19-specific T... IL-2 Carmustine Etoposide Cytarabine Melphalan | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma | NCT00994643 | High Risk Non-H... | Rituximab Interleukin-2 | 18 Years - | Thomas Jefferson University | |
| Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma | NCT00878254 | Mantle-Cell Lym... | G-CSF Rituximab Cyclophosphamid... Cytarabine Doxorubicin Etoposide Ifosfamide Leucovorin Mesna Methotrexate Vincristine | 18 Years - | University of Miami | |
| Safety Study of NHL With 90Y-hLL2 IgG | NCT00421395 | NHL B-cell NHL Non-Hodgkins Ly... | 90Y-hLL2 | 18 Years - | Gilead Sciences | |
| Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab | NCT00724971 | Lymphoma, B-Cel... | Inotuzumab Ozog... Rituximab (Ritu... | 20 Years - 75 Years | Pfizer | |
| Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL | NCT01728207 | Non-hodgkin's L... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Chronic Lymphoc... Small Lymphocyt... | IMMU-114 | 18 Years - | Gilead Sciences | |
| Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies | NCT00048737 | Lymphoma Leukemia | Zevalin Radioim... Rituximab Fludarabine Cyclophosphamid... Allogeneic Stem... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin | NCT00268853 | Diffuse Large-C... | CPOP-R CHOP-R | 18 Years - | CTI BioPharma | |
| Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma | NCT01239394 | Follicular Lymp... Marginal Zone L... Small Lymphocyt... | ofatumumab | 18 Years - | Massachusetts General Hospital | |
| Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. | NCT02670317 | Lymphoma, B-Cel... | Obinutuzumab Ibrutinib CHOP | 18 Years - 60 Years | Fondazione Italiana Linfomi - ETS | |
| Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL | NCT04240704 | Non-Hodgkins Ly... Chronic Lymphoc... | JBH492 | 18 Years - | Novartis | |
| A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma | NCT00452127 | Non-Hodgkin's L... | PRO131921 | 18 Years - | Genentech, Inc. | |
| A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | NCT05828589 | Relapsed Non-Ho... Refractory Non-... Relapsed Chroni... Refractory Chro... Relapsed Follic... Relapsed Margin... Relapse Diffuse... Relapsed Small ... Refractory Foll... Refractory Marg... Refractory Smal... Richter Transfo... Refractory Diff... Transformed Non... | BGB-21447 | 18 Years - | BeiGene | |
| Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma | NCT00115193 | Non-Hodgkin's L... | pegfilgrastim pegfilgrastim | 18 Years - | Amgen | |
| Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma | NCT00285428 | Non-Hodgkin's L... | hA20-humanized ... | 18 Years - | Gilead Sciences | |
| Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies | NCT00670592 | Non-Hodgkin's L... Hodgkin's Lymph... | HCD122 | 18 Years - | Novartis | |
| Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant | NCT00901225 | Multiple Myelom... Non-Hodgkins Ly... Hodgkins Diseas... | G-CSF plus Pler... | 18 Years - 75 Years | Duke University | |
| Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma | NCT00810576 | Lymphoma | Vorinostat Bortezomib | 18 Years - | M.D. Anderson Cancer Center | |
| CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) | NCT03768310 | Non-hodgkin Lym... Acute Lymphobla... | CD19.CAR-multiV... CD19.CAR-multiV... | 1 Year - 75 Years | Baylor College of Medicine | |
| Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia | NCT02952508 | Waldenstrom Mac... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... Mantle Cell Lym... Diffuse Large B... Central Nervous... | Iopofosine I 13... Iopofosine I 13... Iopofosine I 13... | 18 Years - | Cellectar Biosciences, Inc. | |
| Autologous Transplant Using Dose-Escalated Total Body Irradiation & Cyclophosphamide & Palifermin for NHL | NCT03042585 | Relapsed Non Ho... Refractory Non-... | Total body irra... | 18 Years - | Loyola University | |
| A Study Of Panobinostat In Children With Refractory Hematologic Malignancies | NCT01321346 | Lymphoblastic L... Myelogenous Leu... Hodgkin's Disea... Non-Hodgkin's L... | Panobinostat Cytarabine Panobinostat | 8 Years - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | NCT00992446 | Adult Diffuse L... B-Cell Non-Hodg... Follicular Lymp... Mantle Cell Lym... Non-Hodgkin Lym... T-Cell Non-Hodg... | Autologous Hema... Bortezomib Carmustine Cytarabine Etoposide Melphalan Rituximab Vorinostat | 18 Years - | Fred Hutchinson Cancer Center | |
| Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma | NCT00577629 | Lymphoma, B-Cel... | cyclophosphamid... etoposide rituximab cytarabine doxorubicin tositumomab | 18 Years - | Duke University | |
| Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies | NCT01471067 | Blood And Marro... Leukemia Lymphoma Transplantation... Transplantation... | Melphalan Fludarabine Mycophenolate m... Tacrolimus Cord Blood Infu... Rituximab ATG Busulfan Clofarabine Total Body Irra... | 1 Year - 80 Years | M.D. Anderson Cancer Center | |
| A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable | NCT00876122 | Non-Hodgkin's L... | GDC-0941 | 18 Years - | Genentech, Inc. | |
| Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL | NCT05702853 | B-cell Non Hodg... Chronic Lymphoc... | Cyclophosphamid... Fludarabine Inj... CD19-CD34t meta... | 18 Years - | Medical University of South Carolina | |
| Carfilzomib Plus Belinostat in Relapsed/Refractory NHL | NCT02142530 | Non-Hodgkin Lym... Diffuse Large B... Mantle Cell Lym... Follicular Lymp... Peripheral T-ce... | Carfilzomib Belinostat | 18 Years - | Massachusetts General Hospital | |
| Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL | NCT01914744 | Non-Hodgkin Lym... Hepatitis B Rea... | Entecavir Lamivudine | 18 Years - 80 Years | Fudan University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
